In GC, the expression of NFE2L2 has been linked to several aggressive cancer characteristics, such as larger tumor size, increased tumor depth, lymph node metastasis, lymphovascular invasion, higher tumor stage, and poorer survival, and is also linked to resistance to 5‐FU–based chemotherapy [52]. The gene discussed is NFE2L2; the disease is cancer.